Acadia Healthcare Company (ACHC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Mar, 2026Executive summary
Annual meeting scheduled for May 6, 2026, with voting available online or in person.
Shareholders are encouraged to review proxy materials and vote by May 5, 2026.
Voting matters and shareholder proposals
Election of three directors: Michael J. Fucci, Patrice A. Harris, M.D., M.A., and Daniel J. Cancelmi, all recommended by the board.
Approval sought for a second amendment to the Amended and Restated Incentive Compensation Plan.
Advisory vote on executive compensation (say-on-pay) included.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Acadia Healthcare Company
- Q2 2026 saw flat revenue, lower earnings, and raised guidance amid expansion and legal costs.ACHC
Q2 2026 - Strong demand and record bed growth drive steady financial performance and expansion.ACHC
BofA Securities 2025 Healthcare Conference - Revenue up 7.6%, Adjusted EBITDA exceeds guidance, but EPS down on higher legal and tax costs.ACHC
Q1 2026 - 2026 growth hinges on ramping new beds, operational discipline, and improved cash flow.ACHC
47th Annual Raymond James Institutional Investor Conference - Proxy covers director elections, incentive plan amendment, say-on-pay, and auditor ratification.ACHC
Proxy filing - Operational focus shifts to filling new beds, managing policy headwinds, and reducing debt.ACHC
Barclays 28th Annual Global Healthcare Conference - Organizational changes and cost controls aim to boost growth as CapEx drops and debt reduction takes priority.ACHC
Leerink Global Healthcare Conference 2026 - 2026 guidance projects modest growth, lower CapEx, and margin pressure from regulatory headwinds.ACHC
Q4 2025 - Q3 revenue up 8.7% to $816M; guidance trimmed amid volume softness and facility closures.ACHC
Q3 2024